[Efficiency and safety of carvedilol treatment in high risk hypertensive patients].
To evaluate the efficiency and safety of carvedilol treatment in high risk hypertensive patients. Carvedilol was administered in 379 hypertensive patients with high risk factors such as NIDDM, lipid disorders or abnormal serum creatinine level and 364 primary hypertensive patients without risk factors. Before and after treatment with carvedilol, blood pressure, heart rate, serum glucose, lipid profile and serum creatinine level were tested. After treatment, the blood pressure and heart rate were reduced significantly and there was no difference between the two groups. After treatment, the serum glucose, TC, TG and LDL in the high risk group, were reduced from 6.13, 5.37, 2.29 mmol/L and 3.04 to 5.80, 5.11, 2.05 and 2.87 mmol/L respectively (P < 0.001). TC was also reduced in the primary hypertensive group after treatment from 4.73 mmol/L to 4.69 mmol/L (P < 0.01). The efficiency rate of treatment in the high risk group and the primary hypertensive group was 97.75% and 98.32%; there is no statistical difference. The efficiency and safety of carvedilol in the high risk hypertensive patients is same as in the primary hypertensive patients.